The VAT Tax and Duty Manual has been updated to include new guidance setting out the VAT treatment of Blood and Blood Plasma Products which comes into effect on 01 January 2020.
The Court of Justice of the European Union’s (CJEU) judgement in Case C-412/15 TMD held that human blood plasma intended to be used in the manufacturing of pharmaceutical products is subject to VAT. This VAT treatment takes effect from 01 January 2020.
Revenue previously treated pharmaceutical products derived from human blood plasma as exempt from VAT. From 01 January 2020, these products will be subject to VAT.
Source: Deloitte
